As I complete my second year as chief of the Division of Pulmonary and Critical Care Medicine at the University of Virginia, I continue to feel inspired by our faculty.
I feel excited and privileged to be working with so many intelligent, talented, aspiring, and young physicians, nurse practitioners, caretakers, scientists, and staff.
The Division has a rich history and tradition of excellence in patient care, education and research. We currently have 23 faculty members (3 full professors, 3 associate professors, 15 assistant professors, 1 instructor, 1 full research professor, 1 associate research professor, 10 NPs) and 11 clinical pulmonary and critical care fellows. Our faculty members strive to provide the best possible care to patients with a variety of disorders, ranging from obstructive lung diseases in asthma and COPD to pulmonary arterial hypertension, cystic fibrosis, and interstitial lung disease. We also provide the best possible care to the most critically ill patients in the medical intensive care unit. The lung transplant group has been increasing activity while maintaining some of the best outcomes in the nation. These activities allow the division to provide the best training environment for the next generation of physicians and scientists for discoveries in bench, translational and outcomes medicine.
Several of our clinical and research programs have enjoyed continued success. The Cystic Fibrosis foundation continues to recognize our center for excellence under the directorship of Dr. Dana Albon. After many years, of growth under Dr. Eric Davis’ guidance, our Sleep medicine program is now under the steady hand of Dr. Daniel O’Hearn, who joined us from the University of Washington, Seattle, WA. Dr. Mihalek continues his role jointly with Cardiology to run the PAH program. Our COPD center of excellence continues to provide outstanding care under the guidance of Dr. Mike Shim. The ILD program houses expertise in genetics, genomics and clinical trials with participation in numerous industry and NIH sponsored trials. We also engage in cutting-edge bronchoscopic techniques for lung cancer screening and diagnosis.
~ Imre Noth, MD